NCT07007559 Phase 2 Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer Study sponsor: ALX Oncology Inc.
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2027-12 Estimated
Enrollment · participants 120 Estimated
Source updated 2026-09-25 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-04-07 · 4 fields changed
Primary outcomes · main study measures Text edit · unverified significance − Previous value measure: MBC substudy: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment
+ Updated value measure: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment
The saved outcome text may be shortened. Check the source for full wording.
Enrollment · participant count Recorded edit − Previous value count: 80; type: ESTIMATED
+ Updated value count: 120; type: ESTIMATED
Primary completion date Recorded edit
Phase Recorded edit − Previous value PHASE1, PHASE2
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial